



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/21/000126

To,

M/s Bioagile Therapeutics Private Limited,
No. 17/51, 11 Cross, 1st Main Moodalapalya,
Bangalore (India) – 560072.

Sir,

With reference to your application No. GCT/CT04/FF/2021/28395 (GCT/126/21) dated 02-10-2021, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure”, Protocol Number: COVID19-311, Protocol Version 6.0 dated 30/04/2021** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) the Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- (v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

- (xviii) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xix) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

VENUGOPAL
GIRDHARILAL
SOMANI

Digitally signed by VENUGOPAL
GIRDHARILAL SOMANI
DN: cn=IRL, o=MINISTRY OF HOME AFFAIRS,
ou=CDSCO DGHS, postalCode=431401,
st=Maharashtra,
2.5.4.20=172803345d862d489632379a1471
bfdae90b2bea56c83bfbe2154e399b1af7,
c=VENUGOPAL GIRDHARILAL SOMANI
Date: 2021.11.02 14:39:49 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s Bioagile Therapeutics Private Limited, No. 17/51, 11 Cross, 1st Main Moodalapalya, Bangalore (India) – 560072.** to conduct clinical trial of the new drug or investigational new drug as per **Protocol Number: COVID19-311, Protocol Version 6.0 dated 30/04/2021** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

VENUGOPAL
GIRDHARILA
L SOMANI

Digitally signed by VENUGOPAL GIRDHARILA SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS,
ou=CDSCO DGHS, postalCode=431401,
st=Maharashtra,
2.5.4.20=173d03345df62d489632379a14
71bfdae06b2be56c83b3b2154e399b
1a7, cn=VENUGOPAL GIRDHARILA
SOMANI
Date: 2021.11.02 14:39:58 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	INO-4800
Therapeutic class:	Vaccine
Dosage form:	Vaccines (Liquid)
Composition:	Particulates<10micrometer <=6000.0000 number in House Specification Individual Impurity Purity AEC-HPLC Supercoiled >=80.0000 % in House Specification Active Purity AEC-HPLC Circular >=85.0000 % in House Specification Active Quantity of Nucleic Acid Concentration 85.0000 to 15.0000 % in House Specification Active
Indications:	Prophylactic Vaccine against COVID-19

Annexure:

Details of clinical trial site:

Names and address of clinical trial site	Ethics committee details	Name of investigator
Lifepoint Multispecialty Hospital, 145/1, Mumbai Address: Bangalore Highway, Near Hotel Sayaji, Wakad Pune-411057, Maharashtra, India	Lifepoint Multispecialty Hospital, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad Pune-411057, Maharashtra, India ECR/751/Inst/MH/2015/RR-21	Dr .Nirhali Sonali Chandrakant
St. George Hospital ,Grant Government Medical College and Sir J J Group of Hospitals PD Mello Road, CST Mumbai 400001, Maharashtra ,India	Institutional Ethics Committee, Department of Pharmacology, Grant government Medical College & Sir J.J group of Hospitals, Byculla, Mumbai 400008, Maharashtra. India ECR/382/Inst/MH/2013/RR-19	Dr. Akash Ashokkumar Khobragade
Mahatma Gandhi Mission's (MGM) medical College & Hospital, N-6, Cidco< Aurangabad, 431003, Maharashtra, India	(MGM-ECRHS), Pharmacology Department, MGM Medical College, N-6, CIDCO, Aurangabad, 431003 Maharashtra, India ECR/581/Inst/MH/2014/RR-20	Dr. Anand Marutirao Nikalje
Orchid Speciality Hospital, 2 nd Floor, L-Square, Porwal Road, Sr. No. - 282/3/3, Off. Dhanori, Jakat Naka, Lohgaon, Pune-411047, Maharashtra, India	Orchid Speciality Hospital Ethics Committee, Orchid Speciality Hospital, L-Square, Porwal Road, Sr. No. - 282/3/3, Off. Dhanori, Jakat Naka, Lohgaon, Pune-411047, Maharashtra, India ECR/1089/Inst/MH/2018/RR-21	Dr. Ashish Omprakash Goyal
Ishwar Institute of Health Care, Ishwar Heights 1 st Floor Plot No 7, gut no 6/1, beside Punjabi bhavan, Padegaon, Aurngabad-431002, Maharashtra, India	Ethics Committee of Ishwar Institute of Health Care, Ishwar Institute of Health Care, Ishwar Heights, 3 rd Floor, 'Plot No 7, gut no 6/1, beside Punjabi bhavan, Padegaon, Aurngabad-431002, Maharashtra, India ECR/988/Inst/MH/2017/RR-20	Dr. Patel Zabeeuddin Imtiyazuddin
Deoyani Multispeciality Hospital, Lane No.-4, Plot No 121, Dahanukar Colony, Kothrud, Pune-411038, MH, India	Ethics Committee Deoyani Multispeciality Hospital, Deoyani Multispeciality Hospital, Lane No.-4, Plot No 121, Dahanukar Colony, Kothrud, Pune-411038, MH, India ECR/1298/Inst/MH/2019	Dr. Vaishali Sudhir Patkak
Maharaja Agrasen	IEC Maharaja Agrasen Hospital,	Dr. Manish Kumar Jain

File No. CT/126/21-DCG(I)

Superspecialty Hospital, Central Spine, Agrasen Aspatal Marg, Sector-7, Vidyadhar Nagar, Jaipur, Rajasthan-302039	Maharaja Agrasen Superspecialty Hospital, Central Spine, Agrasen Aspatal Marg, Sector-7, Vidyadhar Nagar, Jaipur, Rajasthan-302039 ECR/1222/Inst/RJ/2019	
Omega Hospital, Mahaveer Circle, Kankanady, Mangalore-575002, Karnataka India	Omega Ethics Committee, Omega Hospital, Mahaveer Circle, Kankanady, Mangalore-575002, Karnataka India ECR/89/Inst/KA/2013/RR-20	Dr. Mukund Kumbla
Radiant Superspecialty Hospital, Sabnis Plot, Near Kalyan Nagar Chowk, Vivekanand Colony, Amravati, Maharashtra 444606	Radiant Superspecialty Hospital Committee, Sabnis Plot, Near Kalyan Nagar Chowk, Vivekanand Colony, Amravati, Maharashtra-444606 ECR/997/Inst/MH/2017/RR-21	Dr. Pavan Subhashchandra Agrawal
Evaa Superspecialty Hospital, B28, 29, Govind Marg, Tilak Nagar, Jaipur, Rajasthan 302004	Dhanvantri Ethical Committee for Human Research, DECHR, Near MandarBus Stand, New Sanganer Rd, Ward 27, Mansarovar Sector 6, Mansarovar, Jaipur, Rajasthan 302020 ECR/1506/Inst/RJ/2021	Dr. Sumit Anand
Jeevan Rekha Hospital Dr. BR Ambedkar Road Belagavi- 590002	Institutional Ethics Committee Jeevan Rekha Hospital, Jeevan Rekha Hospital, Dr. B R Ambedkar Road Belagavi- 590002 ECR/1242/Inst/KA/2019	Dr. Amit Suresh Bhate
Prakhar Hospital Pvt. Ltd., 8/219, Arya Nagar Kanpur -208002	IEC Prakhar Hospital Pvt. Ltd., 8/219 Arya Nagar, Kanpur Nagar, Uttar Pradesh-208002, India ECR/1017/Inst/UP/2017/RR-21	Dr. Jitendra Singh Kushwaha
Medipoint Hospitals Pvt. Ltd., 241/1, New D.P. Road, Aundh, Pune-411007, Maharashtra, India	Penta-Med Ethics Committee, Medipoint Hospitals Pvt. Ltd., 241/1, New D.P. Road, Aundh, Pune-411007, Maharashtra, India ECR/357/Inst/MH/2013/RR-20	Dr. Bhatia Girish Gokuldas